Cargando…

Clinical Outcomes of Moderately Hypofractionated Concurrent Chemoradiotherapy for Newly Diagnosed Glioblastoma

PURPOSE: Hypofractionated radiotherapy (HypoRT) has recently been implemented in patients with glioblastoma (GBM) receiving concurrent temozolomide. Lymphopenia during treatment (LDT) is considered an important prognostic factor of clinical outcomes for GBM. We aimed to investigate the outcomes of H...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Nalee, Lim, Do Hoon, Choi, Jung Won, Lee, Jung-Il, Kong, Doo-Sik, Seol, Ho Jun, Nam, Do-Hyun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Yonsei University College of Medicine 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9892549/ https://www.ncbi.nlm.nih.gov/pubmed/36719016 http://dx.doi.org/10.3349/ymj.2022.0352

Ejemplares similares

Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea
por: Kim, Byung Sup, et al.
Publicado: (2017)

Levetiracetam as a sensitizer of concurrent chemoradiotherapy in newly diagnosed glioblastoma: An open‐label phase 2 study
por: Hwang, Kihwan, et al.
Publicado: (2021)

Phase III randomized trial of autologous cytokine-induced killer cell immunotherapy for newly diagnosed glioblastoma in korea
por: Kong, Doo-Sik, et al.
Publicado: (2016)

Multi-Parametric Deep Learning Model for Prediction of Overall Survival after Postoperative Concurrent Chemoradiotherapy in Glioblastoma Patients
por: Yoon, Han Gyul, et al.
Publicado: (2020)

Survival impact of delaying postoperative chemoradiotherapy in newly-diagnosed glioblastoma patients
por: Zhang, Maochen, et al.
Publicado: (2020)

Outcomes in Newly Diagnosed Elderly Glioblastoma Patients after Concomitant Temozolomide Administration and Hypofractionated Radiotherapy
por: Nguyen, Ludovic T., et al.
Publicado: (2013)

CLRM-06 PROSPECTIVE CLINICAL STUDY OF CONVENTIONALLY FRACTIONATED CONCURRENT CHEMORADIOTHERAPY AND HYPOFRACTIONATED CONCURRENT CHEMORADIOTHERAPY AFTER THE SURGERY OF HIGH-GRADE GLIOMAS
por: Weiyan, Shi
Publicado: (2022)

Ethnic delineation of primary glioblastoma genome
por: Koo, Harim, et al.
Publicado: (2020)

Hypofractionated radiotherapy for newly diagnosed elderly glioblastoma patients: A systematic review and network meta-analysis
por: de Melo, Suely Maymone, et al.
Publicado: (2021)

Integrative radiogenomic analysis for genomic signatures in glioblastomas presenting leptomeningeal dissemination
por: You, Hye Jin, et al.
Publicado: (2016)

Efficacy and Safety of Hypofractionated Radiotherapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme: A Systematic Review and Meta-Analysis
por: Liao, Guixiang, et al.
Publicado: (2019)

Comparison of peripheral leukocyte parameters in patients receiving conventionally and hypofractionated radiotherapy schemes for the treatment of newly diagnosed glioblastoma
por: Greenlund, Lindsey, et al.
Publicado: (2023)

Associations of levetiracetam use with the safety and tolerability profile of chemoradiotherapy for patients with newly diagnosed glioblastoma
por: Seystahl, Katharina, et al.
Publicado: (2022)

Efficacy of hypofractionated preoperative chemoradiotherapy in rectal cancer
por: Cho, Ick Joon, et al.
Publicado: (2023)

Integrative radiogenomic analysis for multicentric radiophenotype in glioblastoma
por: Kong, Doo-Sik, et al.
Publicado: (2016)

Long-term outcomes of concomitant chemoradiotherapy with temozolomide for newly diagnosed glioblastoma patients: A single-center analysis
por: Roh, Tae Hoon, et al.
Publicado: (2017)

The Influence of Biomarker Mutations and Systemic Treatment on Cerebral Metastases from NSCLC Treated with Radiosurgery
por: Lee, Min Ho, et al.
Publicado: (2017)

A phase II open label, single arm study of hypofractionated stereotactic radiotherapy with chemoradiotherapy using intensity-modulated radiotherapy for newly diagnosed glioblastoma after surgery: the HSCK-010 trial protocol
por: Guan, Yun, et al.
Publicado: (2022)

Clinical and Radiological Characteristics of Angiomatous Meningiomas
por: Hwang, Juyoung, et al.
Publicado: (2016)

Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter
por: Lim, Michael, et al.
Publicado: (2022)

Accelerated Hypofractionated Radiotherapy in the Era of Concurrent Temozolomide Chemotherapy in Elderly Patients with Glioblastoma Multiforme
por: Greer, Liana, et al.
Publicado: (2017)

Harnessing Nuclear Energy to Gold Nanoparticles for the Concurrent Chemoradiotherapy of Glioblastoma
por: Li, Jui-Ping, et al.
Publicado: (2023)

Clinical outcomes of patients with multiple courses of radiosurgery for brain metastases from non-small cell lung cancer
por: Lee, Won-Jae, et al.
Publicado: (2022)

Effect of Bevacizumab Treatment in Cerebral Radiation Necrosis : Investigation of Response Predictors in a Single-Center Experience
por: Lee, Shin Heon, et al.
Publicado: (2023)

Gamma Knife Radiosurgery for Brain Metastases from Breast Cancer
por: Jo, Kyung Il, et al.
Publicado: (2013)

Journey to hypofractionation in radiotherapy for breast cancer: critical reviews for recent updates
por: Kim, Nalee, et al.
Publicado: (2022)

Chloroquine combined with concurrent radiotherapy and temozolomide for newly diagnosed glioblastoma: a phase IB trial
por: Compter, Inge, et al.
Publicado: (2020)

Avelumab in newly diagnosed glioblastoma
por: Jacques, Francois H, et al.
Publicado: (2021)

Identification of prognostic biomarkers for glioblastomas using protein expression profiling
por: JUNG, YONG, et al.
Publicado: (2011)

Therapeutic Strategy for Cavernous Sinus-Invading Non-Functioning Pituitary Adenomas Based on the Modified Knosp Grading System
por: Hwang, Juyoung, et al.
Publicado: (2016)

Study Protocol: Prospective Study of Concurrent Chemoradiotherapy with S-1 and Hypofractionated Radiotherapy for Outpatients with Early Glottic Squamous Cell Carcinomas
por: Kimura, Kana, et al.
Publicado: (2018)

Do Biliary Complications after Hypofractionated Radiation Therapy in Hepatocellular Carcinoma Matter?
por: Yu, Jeong Il, et al.
Publicado: (2016)

Identification of transcriptome signature for predicting clinical response to bevacizumab in recurrent glioblastoma
por: Choi, Seung Won, et al.
Publicado: (2018)

Treatment Outcomes of Pediatric Craniopharyngioma : A 15-Year Retrospective Review of 35 Cases
por: Jo, Kwang Wook, et al.
Publicado: (2012)

Are three weeks hypofractionated radiation therapy (HFRT) comparable to six weeks for newly diagnosed glioblastoma patients? Results of a phase II study
por: Navarria, Pierina, et al.
Publicado: (2017)

Scalp-Sparing Radiation With Concurrent Temozolomide and Tumor Treating Fields (SPARE) for Patients With Newly Diagnosed Glioblastoma
por: Miller, Ryan, et al.
Publicado: (2022)

Long-term outcomes of concomitant chemoradiotherapy with temozolomide for newly diagnosed glioblastoma patients: A single-center analysis: Erratum
Publicado: (2017)

Recent Updates on Radiation Therapy for Pediatric Optic Pathway Glioma
por: Kim, Nalee, et al.
Publicado: (2022)

Advances in the treatment of newly diagnosed glioblastoma
por: Theeler, Brett J., et al.
Publicado: (2015)

A Review of Newly Diagnosed Glioblastoma
por: Oronsky, Bryan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9enbnvl4b3d0r5hlstq6655vt1